Xencor stock falls 3.52 percent as Truist lifts its target
Xencor's stock dropped by 3.52% to EUR 21.90 on September 29, 2026, despite Truist reiterating its Buy rating and raising its price target to USD 29.00. The biotechnology company, with a market capitalization of USD 1.8 billion, reported a 17.40% increase in Q2 revenue to USD 51.22 million, and a narrower adjusted EPS loss of USD 0.29, beating analyst expectations. However, the stock remains below its 52-week high of USD 30.61.
Truist raises Xencor stock price target to $29 on drug trial outlook
Truist Securities has increased its price target for Xencor, Inc. (NASDAQ:XNCR) to $29 from $27, maintaining a Buy rating. This adjustment comes ahead of the upcoming ESMO update for XmAb819, a key drug trial event the firm expects to positively influence Xencor's stock, given its significant 106% gain over the past year. Xencor also recently announced Phase 1 study results for its XmAb819 antibody will be presented at the European Society of Medical Oncology Congress 2026, focusing on advanced clear cell renal cell carcinoma.
Truist Financial Maintains Xencor(XNCR.US) With Buy Rating, Announces Target Price $29
Truist Financial has reaffirmed its Buy rating for Xencor (XNCR.US) and set a price target of $29. This indicates the firm's continued confidence in the biotechnology company's stock performance.
Xencor (NASDAQ:XNCR) Earns Buy Rating from Truist Financial
Truist Financial has reiterated its "buy" rating on Xencor (NASDAQ:XNCR) and increased its price target from $27 to $29, suggesting a 16.5% upside. This positive outlook aligns with a broader "Moderate Buy" consensus among analysts, with an average price target of $31.38. Xencor also reported strong quarterly results, exceeding analyst expectations with a smaller-than-anticipated loss and significant revenue growth.
Truist raises Xencor stock price target to $29 on drug trial outlook
Truist Securities has increased its price target for Xencor, Inc. (NASDAQ: XNCR) to $29 from $27, maintaining a Buy rating. The firm anticipates a key event with the upcoming ESMO update for XmAb819 on October 25, assigning a 70% probability of favorable outcomes. Xencor's stock has already seen a 106% gain over the past year, and Truist estimates peak revenue for XmAb819 at around $800 million.
Truist Securities reiterates Buy rating on Xencor, $29 price target
Truist Securities has reiterated its Buy rating on Xencor's stock, setting a price target of $29.00, which suggests a 21.8% upside from the recent closing price. This positive outlook is supported by promising clinical data for Xencor's XmAb819 in clear cell renal cell carcinoma, showing encouraging overall response rates and median progression-free survival, alongside a favorable safety profile. The analyst note highlights the potential for XmAb819 to advance to a pivotal study.
Truist raises Xencor stock price target to $29 on drug trial outlook
Truist Securities has increased its price target for Xencor, Inc. (NASDAQ:XNCR) to $29 from $27, maintaining a Buy rating. The adjustment follows Xencor's significant stock gain and ahead of an important ESMO update for its drug XmAb819, which Truist anticipates will support advancement to Phase III. The firm projects XmAb819 peak revenue around $800 million, primarily from treating clear cell renal cell carcinoma, and sees potential for further upside.
Xencor, Inc. $XNCR Shares Newly Bought by Bank of America Corp DE
Bank of America Corp DE has acquired 360,396 shares of Xencor, Inc. (NASDAQ:XNCR) in the second quarter, valued at approximately $5.8 million. Other institutional investors like BlackRock Inc. and Primecap Management Co. CA also initiated new positions, while BVF Inc. IL significantly increased its stake. Xencor reported a smaller-than-expected quarterly loss of $0.29 per share and a 17.4% year-over-year revenue increase to $51.22 million, with analysts maintaining a "Moderate Buy" rating and an average price target of $31.12.
Wedbush Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $30
Wedbush has reiterated its Buy rating on Xencor (XNCR.US), maintaining a target price of $30. This suggests the firm continues to see strong potential in the company's stock.
Xencor stock falls 1.57 percent as BofA raises target
Xencor stock fell 1.57% to USD 23.88 on September 24, 2026, despite Bank of America raising its price target from USD 20 to USD 26 while maintaining a Neutral rating. The biotechnology company's second-quarter revenue increased by 17.4% year-over-year, and its adjusted EPS outperformed consensus estimates. Xencor's valuation is largely tied to its clinical pipeline progress, with its stock remaining 22% below its 52-week high.
Discipline and Rules-Based Execution in XNCR Response
This article analyzes Xencor Inc. (NASDAQ: XNCR), highlighting a potential mid-term weak bias despite long-term strength. It presents AI-generated trading strategies including long, breakout, and short setups with specific entry, target, and stop-loss levels. The analysis emphasizes a high risk-reward short setup targeting 21.2% downside against 0.3% risk.
BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating
BofA has increased its price target for Xencor (XNCR) from $20 to $26, while maintaining a Neutral rating on the stock. According to analysts, Xencor currently holds an average rating of overweight and a mean price target of $31.25. The article highlights this update in financial analysis for Xencor.
Xencor Is Maintained at Neutral by B of A Securities
B of A Securities has reiterated its "Neutral" rating on Xencor (NASDAQ: XNCR) stock. The firm provided a price target of $28.00 for the biopharmaceutical company.
XENCOR, INC. : BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $26 FROM $20
BofA Global Research has increased its price objective for Xencor, Inc. (XNCR.O) from $20 to $26. This adjustment reflects an updated outlook from the research firm regarding the biotechnology company's valuation. The report was issued by Reuters.
Xencor (NASDAQ:XNCR) Price Target Raised to $26.00
Bank of America raised its price target for Xencor (NASDAQ:XNCR) from $20.00 to $26.00, maintaining a "neutral" rating, which implies a potential upside of 4.78%. Other analysts have also issued positive ratings, contributing to a "Moderate Buy" consensus and an average price target of $31.12. Xencor's shares recently rose by 0.4%, and the company's last quarterly results exceeded expectations, reporting a smaller loss per share and higher revenue than estimated.
BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating
BofA has increased its price target for Xencor (XNCR) from $20 to $26, while maintaining a Neutral rating on the stock. This adjustment reflects an updated outlook from the bank regarding the biopharmaceutical company. Xencor, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered antibodies for cancer and autoimmune diseases, with several candidates in clinical development.
Xencor stock steadies after recent earnings, analysts watch pipeline progress
Xencor's stock remains steady as investors evaluate the company's latest quarterly financials, which show continued high R&D spending leading to a net loss, alongside revenues from licensing and collaboration. The biotech firm's future growth hinges on its engineered antibody and cytokine pipeline, with analysts focusing on clinical trial progress and the company's cash runway. While near-term losses are noted, the long-term value is tied to successful pipeline advancements and potential future royalty streams, positioning Xencor as a mid-cap biotech play with typical sector volatility.
Hsbc Holdings PLC Has $2.08 Million Position in Xencor, Inc. $XNCR
Hsbc Holdings PLC significantly increased its stake in Xencor, Inc. by 114.2% in the second quarter, now holding 125,482 shares valued at $2.08 million. Other hedge funds like BlackRock Inc. and Primecap Management Co. CA also acquired substantial new stakes in the biopharmaceutical company. Analysts currently rate Xencor with a "Moderate Buy" and an average price target of $31.86, following recent price target adjustments and ratings changes.
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 260,752 Shares of Xencor, Inc. $XNCR
UBS Asset Management Americas LLC significantly increased its stake in Xencor, Inc. (NASDAQ:XNCR) by 214.9% in the second quarter, acquiring an additional 260,752 shares to bring its total to 382,094 shares valued at $6.15 million. This move comes as Xencor reported better-than-expected quarterly results, with an adjusted loss of $0.29 per share against an estimated $0.80 loss, and revenue growth of 17.4% year-over-year to $51.22 million. Analyst sentiment for Xencor is generally positive, holding a "Moderate Buy" rating with an average price target of $30.71.
The Manufacturers Life Insurance Company Buys Shares of 49,696 Xencor, Inc. $XNCR
The Manufacturers Life Insurance Company has acquired a new stake of 49,696 shares in Xencor, Inc. (NASDAQ:XNCR), valued at approximately $800,000, representing a 0.07% ownership. This move comes as Xencor reported better-than-expected quarterly results with a smaller loss per share and higher revenue than anticipated. Analysts currently maintain a "Moderate Buy" rating for Xencor with an average price target of $30.71.
Seven Fleet Capital Management LP Has $5.93 Million Stake in Xencor, Inc. $XNCR
Seven Fleet Capital Management LP significantly increased its stake in Xencor, Inc. (NASDAQ:XNCR) by 360.4% in the second quarter, bringing its total holding to 368,305 shares valued at $5.93 million. This comes as other institutional investors, including UBS Asset Management and Susquehanna International Group, also boosted their positions in the biopharmaceutical company. Analysts have a "Moderate Buy" consensus rating for Xencor, with a target price of $30.71, following the company's strong quarterly earnings beat where it surpassed both EPS and revenue estimates.
Man Group plc Takes Position in Xencor, Inc. $XNCR
Man Group plc has acquired a new position in Xencor, Inc. (NASDAQ:XNCR), purchasing 58,380 shares valued at approximately $940,000. This move aligns with a generally positive outlook from analysts, who have given Xencor a "Moderate Buy" rating with an average price target of $30.71. The biopharmaceutical company recently reported strong quarterly results, exceeding revenue and earnings per share estimates.
Bank of New York Mellon Corp Makes New Investment in Xencor, Inc. $XNCR
Bank of New York Mellon Corp has acquired a new position in Xencor, Inc. (NASDAQ:XNCR), purchasing 410,769 shares valued at approximately $6.6 million. This investment comes as several other institutional investors have also adjusted their holdings in the biopharmaceutical company. Xencor reported a stronger-than-expected quarter, with analysts generally maintaining a "Moderate Buy" rating and an average price target of $30.71.
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Xencor (NASDAQ:XNCR) Stock
JPMorgan Chase & Co. has raised its price target for Xencor (NASDAQ:XNCR) from $14 to $21, though it maintains a "neutral" rating, indicating a potential 21% downside from the current price of $26.62. Despite this, Xencor holds a "Moderate Buy" consensus rating among analysts with an average target of $30.71. The biopharmaceutical company recently surpassed quarterly expectations, reporting a smaller adjusted loss of $0.29 per share against an anticipated $0.80 loss, and achieving revenue of $51.22 million, a 17.4% increase year-over-year.
Technical Reactions to XNCR Trends in Macro Strategies
This article analyzes Xencor Inc. (NASDAQ: XNCR) trends using AI models to generate trading strategies. It highlights weak near-term sentiment, compelling upside potential with no resistance levels, and overall positive sentiment. Three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—are provided with specific entry, target, and stop-loss levels, alongside multi-timeframe signal analysis.
Xencor to Present at the 2026 Cantor Global Healthcare Conference
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company, announced that its management will present at the 2026 Cantor Global Healthcare Conference. The presentation is scheduled for Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT. A live webcast and replay will be available through the Investors section of Xencor’s website.
Xencor (XNCR) Maintained by Raymond James -- Price Target Raised to $46
Raymond James has maintained a "Strong Buy" rating on Xencor (XNCR) and raised its price target from $40.00 to $46.00. Despite this positive analyst outlook, GuruFocus indicates that Xencor is significantly overvalued at $27.42 compared to its GF Value™ of $10.49, with a low GF Score™ of 40/100 primarily due to weak profitability and valuation. Investors are advised to exercise caution due to the high overvaluation and notable insider selling activity.
Legal & General Group Plc Acquires Shares of 1,091,177 Xencor, Inc. $XNCR
Legal & General Group Plc recently acquired over 1 million shares of Xencor, Inc. (NASDAQ:XNCR) during the second quarter, valued at approximately $17.6 million, representing a 1.47% stake. Xencor reported a quarterly loss of $0.29 per share, beating consensus estimates, and saw its revenue increase by 17.4% year-over-year. The stock currently holds a "Hold" consensus rating from analysts, with shares trading at $26.06 against an average target price of $24.86.
Hsbc Holdings PLC Buys Shares of 125,482 Xencor, Inc. $XNCR
Hsbc Holdings PLC acquired 125,482 shares of Xencor, Inc. (NASDAQ:XNCR) in the second quarter, a new position valued at approximately $2.08 million. Xencor recently reported stronger-than-expected quarterly results, with an adjusted loss of $0.29 per share against an estimated $0.80 loss, and revenue of $51.22 million, representing a 17.4% year-over-year increase. Despite mixed analyst ratings, the company's stock has seen significant institutional investor activity and has a market cap of $1.94 billion.
Deutsche Bank AG Acquires New Shares in Xencor, Inc. $XNCR
Deutsche Bank AG has acquired a new stake in Xencor, Inc. (NASDAQ:XNCR), purchasing 119,822 shares valued at approximately $1.93 million, representing 0.16% of the biopharmaceutical company. Other hedge funds also adjusted their positions in Xencor. The company's Q2 earnings exceeded expectations with revenue up 17.4% year-over-year, although analyst sentiment remains mixed with a consensus "Hold" rating.
BlackRock Inc. Buys Shares of 13,651,261 Xencor, Inc. $XNCR
BlackRock Inc. has acquired 13.65 million shares of Xencor, Inc. (NASDAQ:XNCR) for approximately $219.8 million, establishing an 18.41% stake in the biopharmaceutical company. This comes as Xencor reported a stronger-than-expected quarter with a narrower loss per share and increased revenue. Despite XNCR shares rising near their 52-week high, analysts maintain a "Hold" rating with an average price target of $24.86.
368,305 Shares in Xencor, Inc. $XNCR Bought by Seven Fleet Capital Management LP
Seven Fleet Capital Management LP acquired 368,305 shares of Xencor, Inc. ($XNCR) in the second quarter, making it their 17th largest holding with a 0.50% stake. Despite mixed analyst ratings, Xencor recently reported better-than-expected quarterly results, exceeding revenue and EPS estimates. The company's stock currently holds a consensus "Hold" rating with an average target price of $24.86.
Primecap Management Co. CA Invests $163.92 Million in Xencor, Inc. $XNCR
Primecap Management Co. CA has acquired a significant new stake of $163.92 million in biopharmaceutical company Xencor, Inc. (NASDAQ:XNCR), totaling 10.18 million shares and representing a 13.69% ownership. Other institutional investors like BlackRock and Vanguard also hold substantial positions, with Xencor recently reporting a narrower-than-expected quarterly loss and exceeding revenue estimates. Despite a consensus "Hold" rating from analysts, the stock has shown strong price performance, opening at $29.30, near its one-year high.
ADAR1 Capital Management LLC Invests $3.74 Million in Xencor, Inc. $XNCR
ADAR1 Capital Management LLC has invested $3.74 million in Xencor, Inc. (NASDAQ:XNCR) by acquiring 232,560 shares during the second quarter. Other hedge funds have also increased their positions in the biopharmaceutical company, which recently reported better-than-expected earnings with revenue up 17.4% year-over-year. Analysts currently have a consensus "Hold" rating on Xencor, with an average price target of $24.86.
Xencor (NASDAQ:XNCR) Reaches New 52-Week High - Here's Why
Xencor (NASDAQ:XNCR) shares recently hit a new 52-week high of $28.4590, driven by the company exceeding its quarterly revenue and earnings estimates. Analysts' sentiment is mixed, with a consensus "Hold" rating and an average price target of $24.86, despite some recent upgrades. The biopharmaceutical company specializes in engineered protein therapeutics for autoimmune diseases, cancer, and neurological disorders.
Is Xencor (XNCR) Undervalued After Its Recent Share Price Surge?
Xencor (XNCR) has seen a significant surge in its share price recently, with a 32.03% return over the last 30 days and 262.90% over the past year. Despite this, the company is still considered 5.3% undervalued against a fair value of $28.50, driven by its robust XmAb platform and efficient clinical trial strategy. However, potential risks include increased competition in TL1A programs and possible delays or underwhelming data from key trials like XmAb942 or XmAb412.
103,736 Shares in Xencor, Inc. $XNCR Bought by DCF Advisers LLC
DCF Advisers LLC recently acquired 103,736 shares of Xencor, Inc. (NASDAQ:XNCR) during the second quarter, establishing a new position valued at approximately $1.67 million. Other institutional investors also adjusted their holdings in the biopharmaceutical company, which recently reported better-than-expected quarterly revenue of $51.22 million and an adjusted loss of $0.29 per share. Despite trading near its 12-month high, analysts maintain an overall "Hold" rating for Xencor with an average price target of $24.86.
Xencor stock hits 52-week high at 26.18 USD
Xencor Inc.'s stock reached a 52-week high of $26.18 USD, reflecting a significant 238.35% increase over the past year and substantial year-to-date and six-month returns. The biotechnology company, with a market capitalization of $1.93 billion, is advancing its pipeline, including presenting Phase 1 study results for its XmAb819 antibody at the European Society of Medical Oncology Congress 2026. Despite its strong performance, an InvestingPro analysis suggests the stock is overvalued relative to its Fair Value.
Do Xencor’s (XNCR) Mixed 2026 Loss Trends Hint at Shifting Cost Discipline?
Xencor, Inc. reported a mixed financial performance for Q2 2026, showing a reduced net quarterly loss of US$21.73 million, yet an expanded net loss of US$150.65 million for the first half of the year. This disparity suggests uneven cost management, prompting investors to consider whether future clinical milestones for its TL1A-focused pipeline, particularly XmAb942, can offset widening losses and potential dilution risks from ongoing high R&D spending. The company's investment narrative projects significant revenue and earnings growth by 2029, with some analysts presenting even more optimistic forecasts.
Do Xencor’s (XNCR) Mixed 2026 Loss Trends Hint at Shifting Cost Discipline?
Xencor, Inc. reported a narrower net loss of US$21.73 million for Q2 2026 but a wider net loss of US$150.65 million for the first half of 2026. This mixed financial performance highlights the company's uneven cost profile and continued lack of profitability, despite ongoing R&D investment in its TL1A-focused pipeline. Investors face the challenge of balancing future clinical milestones against the risk of capital raising and dilution due to widening year-to-date losses.
Analysts' Revenue Estimates For Xencor, Inc. (NASDAQ:XNCR) Are Surging Higher
Xencor, Inc.'s revenue estimates have been significantly upgraded by analysts, signaling increased optimism for the company's future performance. This positive revision comes despite the company not having current revenues, as analysts anticipate strong growth. The upgraded forecasts suggest a bright outlook for Xencor, Inc. in the coming years.
Industry Analysts Just Made A Huge Upgrade To Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts
Industry analysts have significantly upgraded their revenue forecasts for Xencor, Inc. (NASDAQ:XNCR) for 2026, with the consensus estimate now at US$144 million, a 37% increase from the previous year's sales. This revised outlook suggests a much more bullish perspective on the company's prospects, forecasting an 88% annualized growth rate, outperforming the broader industry's 23% annual growth expectation. Despite the upgraded revenue targets, the consensus price target remains unchanged at US$29.00.
Industry Analysts Just Made A Huge Upgrade To Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts
Industry analysts have significantly upgraded their revenue forecasts for Xencor, Inc. (NASDAQ:XNCR) for 2026, projecting a 37% increase in sales to US$144 million. This increased optimism also suggests that Xencor is expected to grow much faster than the broader industry. Shareholders have already seen a 12% share price gain in the last week, following the positive outlook.
(XNCR) as a Liquidity Pulse for Institutional Tactics
This article analyzes Xencor Inc. (NASDAQ: XNCR) based on AI models, identifying strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with a multi-timeframe signal analysis. The analysis is presented by Stock Traders Daily's Quantitative Research Desk.
Biotech Stocks At 52-Week Highs - BIVI +22%, XNCR, ANRO, HAE, ACAD
Several biotech stocks, including BioVie Inc. (BIVI), Xencor Inc. (XNCR), Alto Neuroscience Inc. (ANRO), Haemonetics Corporation (HAE), and ACADIA Pharmaceuticals Inc. (ACAD), reached 52-week highs on August 12, 2026. These gains were propelled by positive catalysts such as promising clinical trial results, strong quarterly financial reports, and advancements in drug pipelines. The article details the specific developments and financial performance driving each company's stock surge.
Xencor stock hits 52-week high at 21.99 USD
Xencor Inc. (XNCR) has reached a new 52-week high of $21.99, demonstrating a 41% year-to-date return and a 178.71% increase over the past year, reflecting strong investor confidence in the biotechnology company. This growth is attributed to its innovative work in engineered monoclonal antibodies for cancer and autoimmune diseases, with recent positive analyst revisions and upcoming presentation of Phase 1 study results for XmAb819 at ESMO 2026. Despite its strong performance, InvestingPro data suggests the stock might be overvalued relative to its Fair Value.
Xencor (XNCR) Could Be 24% Below Fair Value On Narrower Quarterly Loss
Xencor (XNCR) recently reported a narrower quarterly net loss, reinforcing positive sentiment and leading to significant share price returns over the last month and year. Despite negative 3- and 5-year returns, the company is considered 24.3% undervalued with a fair value of $28.50 compared to its current price of $21.58, driven by expectations of pipeline expansion and future earnings. However, a cross-check of its P/S ratio at 15.3x sales suggests potential valuation risk, trading above the industry average.
Analysts Are Upgrading Xencor, Inc. (NASDAQ:XNCR) After Its Latest Results
Xencor, Inc. (NASDAQ:XNCR) recently released a strong quarterly report, with revenue significantly beating expectations and losses being smaller than predicted. This positive performance has led analysts to upgrade their revenue estimates for 2026 and reduce loss estimates, though the consensus price target remains unchanged. Despite the wide range in analyst price targets, Xencor's revenue growth is now projected to accelerate substantially faster than its historical performance and the wider industry.
Analysts Are Upgrading Xencor, Inc. (NASDAQ:XNCR) After Its Latest Results
Xencor, Inc. recently reported strong quarterly results, with revenue significantly beating expectations and losses being smaller than predicted. This led analysts to upgrade revenue estimates and reduce loss forecasts for 2026, anticipating substantial growth compared to the broader industry. Despite the positive outlook, the consensus price target remained unchanged, indicating continued analyst concern about ongoing losses.
Xencor, Inc. Stock 12‑Month Price Target Raised to $29, Implies 45% Upside
Xencor, Inc. (XNCR) has seen its average 12-month price target raised from $28.75 to $29 by 12 analysts, implying a 45% potential upside from its Aug. 6 closing price. The consensus rating for the stock remains "Buy" among 14 analysts, with 12 recommending a Buy and 2 a Hold.
